SRSofia Chiatamone Ranieri

Sofia Chiatamone Ranieri

*This is an algorithmically generated author record based on publicly available information.

Sofia Chiatamone Ranieri has a total of 62 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnostic performance evaluation of the Siemens Healthineers Atellica HEMA 580 hematology analyzer for abnormal cell detection and optimization of immature myeloid cell cut-offs

    by Vincenzo De Iuliis, Sofia Chiatamone Ranieri

    Objectives: We evaluated the diagnostic performance of the Atellica HEMA 580 hematology analyzer for complete blood count (CBC) parameters compared with the ADVIA 2120i and assessed its capability to flag abnormal cells, and determined optimal cut-offs for immature myeloid cell detection. Methods: A total of 400 K 2 EDTA blood samples were analyzed. Peripheral blood smears were independently reviewed by two clinical pathologists, each performing a 200-cell differential count. Analytical correlation, regression, Bland–Altman, and receiver operating characteristic (ROC) curve analyses were used to assess performance. Optimal cut-offs for immature myeloid cell (IMC) detection were determined using ROC analysis and the Youden index. Results: Manual microscopy identified 23 samples with blasts (≥0.5 %), 177 with immature myeloid cells, and 61 with nucleated red blood cells (NRBCs). ROC analysis showed good accuracy for IMC detection using the IMG (immature granulocytes) parameter (AUC=0.81). An IMG cut-off >0.8 provided the best balance between sensitivity (40.7 %) and specificity (96.9 %), while large immature cells (LICs) >0.9 yielded higher sensitivity (60.5 %) at the expense of specificity (82.5 %). The Atellica HEMA 580 also demonstrated superior NRBC detection compared to ADVIA 2120i. Conclusions: The Atellica HEMA 580 provided reliable performance in detecting immature myeloid cells and NRBCs. The IMG cut-off >0.8, determined through ROC optimization, supports its implementation for enhancing laboratory workflow efficiency while maintaining diagnostic accuracy. These findings support the clinical implementation of the Atellica HEMA 580 for routine hematology laboratories, particularly for enhanced detection of clinically significant immature myeloid populations.

  • Transient Reactive Plasmacytosis: Diagnostic And Clinical Implications

    by Fiamma Balboni, Antonio La Gioia, Tullio Biondi, Roberto Caporale, Cecilia Vitali, Diego La Gioia, Pietro Andrea Accardo, Francesca Accordino, Federico Mayer, Sofia Chiatamone Ranieri

  • Open Access

    Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery

    by Azzurra Irelli, Leonardo Valerio Patruno, Sofia Chiatamone Ranieri, Daniela Di Giacomo, Sara Malatesta, Edoardo Alesse, Alessandra Tessitore, Katia Cannita

    Hereditary breast and ovarian cancer (HBOC) syndrome is responsible for approximately 10% of breast cancers (BCs). The HBOC gene panel includes both high-risk genes, i.e., a four times higher risk of BC (BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11 and TP53), and moderate-risk genes, i.e., a two to four times higher risk of BC (BARD1, CHEK2, RAD51C, RAD51D and ATM). Pathogenic germline variants (PGVs) in HBOC genes confer an absolute risk of BC that changes according to the gene considered. We illustrate and compare different BC risk estimation models, also describing their limitations. These models allow us to identify women eligible for genetic testing and possibly to offer surgical strategies for primary prevention, i.e., risk-reducing mastectomies and salpingo-oophorectomies.


  • Open Access

    Role of the Molecular Tumor Board for the Personalized Treatment of Patients with Metastatic Breast Cancer: A Focus on the State of the Art in Italy

    by Azzurra Irelli, Sofia Chiatamone Ranieri, Daniela Di Giacomo, Sara Malatesta, Leonardo Valerio Patruno, Alessandra Tessitore, Edoardo Alesse, Katia Cannita

    Molecular tumor boards (MTBs) are multidisciplinary groups that combine molecular and clinical data from cancer patients in order to formulate treatment recommendations for precision medicine. To date, there is insufficient data to support the use of singleplex or next-generation sequencing (NGS) technologies to select first-line therapy for patients with metastatic breast cancer (MBC), but considering the high number of level II alterations, according to the ESMO scale for clinical actionability of molecular targets (ESCAT), it is suggested to include patients in molecular screening programs in order to be able to offer targeted therapies for specific genomic alterations. This article aims at reviewing the most recent literature related to the most used methodologies/approaches for molecular diagnostics and variants’ classification, summarizing the internationally published molecular screening studies in support of MTB activity and, in the end, discussing MTBs’ current position and role in Italy, the number of which is increasing, also thanks to the thrust of institutions.


  • Open Access

    Role of conventional cytology and cell block methods for diagnosis of malignant pleural effusions

    by Sofia Chiatamone Ranieri, Gabriella Di Leonardo, Gino Coletti, Antonella Dal Mas, Maria Laura Brancone, Roberto Crisci, Duilio Divisi

    Background: The study evaluates the role of a combined cytological smear (CS) and cell block (CB) approaches in malignant pleural effusion (MPE), highlighting specificity and sensitivity referred to histology and the incidence of different types of malignancies. Methods: We retrospectively included 223 patients over a duration of 5 years. Pleural fluid was collected and CS together with CB were made from the fluid. Immunocytochemical (ICC) stains were applied when requested by pathologist. Histology confirmation and medical records were recorded to confirm or not cytological diagnosis. Results: The combined approach demonstrated a diagnostic accuracy of 95%, 92% sensitivity, 96% specificity, positive predictive value of 92%, negative predictive value of 96%, positive likelihood ratio of 23 and negative likelihood ratio of 0.08. Lung cancer was found to be the commonest (23 cases, 33.8%) malignant neoplasm diagnosed in the pleurae followed by breast cancer (14 cases, 20.6%), gastrointestinal cancer (7 cases, 10.3%) and mesothelioma (6 cases, 8.8%). Conclusions: In our experience the combined approach definitively has proven to have an excellent diagnostic yield in the MPE, allowing to identify the nature of malignant cells in most of patients.


  • Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort

    by Sofia Chiatamone Ranieri, Maria Antonietta Arleo, Stefania Trasarti, Luisa Bizzoni, Ida Carmosino, Maria Lucia De Luca, Sara Mohamed, Elena Mariggiò, Emilia Scalzulli, Serena Rosati, et al.


  • Open Access

    Aplastic Anemia and Good Syndrome in a Heavily Treated Stage IV Thymoma Patient: A Case Report and Review of the Literature

    by Sofia Chiatamone Ranieri, Stefania Trasarti, Maria Antonietta Arleo, Luisa Bizzoni, Livia Bonanni, Valeria Di Battista, Maria Assunta Limongiello, Maria Grazia Nardacci, Giuseppe Gentile, Robin Foà

    Thymoma is an uncommon slowly growing neoplasm. It usually presents with paraneoplastic syndromes including the immunodeficiency syndrome called Good syndrome and hematological disorders. Pure red cell aplasia is a well-recognized complication of thymoma, and aplastic anemia is very rare in association with GS. We report a case of GS in a heavily treated patient with stage IV thymoma associated with a pure red cell aplasia and an amegakaryocytic thrombocytopenia that evolved into an AA and provide an up-to-date review of the relevant literature. This is the first case of the association of GS and AA with the coexistence of a heavily treated stage IV thymoma. The fatal outcome was not related to the progression of the thymoma, but rather to the severe infectious complications. The combination of lymphopenia and hypogammaglobulinemia typical of GS, coupled to the neutropenia, caused by bone marrow failure, was the main predisposing factor for the unfavourable outcome.


  • Open Access

    Diabetes and risk of cancer incidence: results from a population-based cohort study in northern Italy

    by Paola Ballotari, Massimo Vicentini, Valeria Manicardi, Marco Gallo, Sofia Chiatamone Ranieri, Marina Greci, Paolo Giorgi Rossi

    Aim of this study was to compare cancer incidence in populations with and without diabetes by cancer site. Furthermore, we aimed at comparing excess risk of cancer according to diabetes type, diabetes duration and treatment, the latter as regards Type 2 diabetes. By use of the Reggio Emilia diabetes registry we classified the resident population aged 20–84 at December 31st 2009 into two groups: with and without diabetes. By linking with the cancer registry we calculated the 2010–2013 cancer incidence in both groups. The incidence rate ratios (IRR) by cancer site, type of diabetes, diabetes duration, and as concerns Type 2 diabetes, by treatment regimen were computed using Poisson regression model and non-diabetic group as reference. The cohort included 383,799 subjects without diabetes and 23,358 with diabetes. During follow-up, we identified 1464 cancer cases in subjects with diabetes and 9858 in the remaining population. Overall cancer incidence was higher in subjects with diabetes than in those without diabetes (IRR = 1.22, 95%CI 1.15–1.29), with similar results focusing on subjects with at least 2-year diabetes duration. Cancer sites driving overall increased risk were liver, pancreas, Colon rectum, and bladder in both sexes, corpus uteri for females. There was also suggestion of an increased risk for kidney cancer in females and a decreased risk for prostate cancer. Excess risk was found in patients with Type 2 diabetes, more marked among insulin users, especially with combined therapy. We observed an increasing risk for diabetes duration up to 10 years from diagnosis (IRR = 1.44, 95%CI 1.29–1.61) and a subsequent decrease to moderate-higher risk (IRR = 1.15, 95%CI 1.04–1.30). Our study indicates that the strength of association depends on specific cancer site. Insulin, monotherapy or combined therapy, per se or as an indication of poor blood glucose control, in addition to diabetes duration, may play a role in the association of diabetes and cancer.


  • Open Access

    Sex Differences in Cardiovascular Mortality in Diabetics and Nondiabetic Subjects: A Population-Based Study (Italy)

    by Paola Ballotari, Sofia Chiatamone Ranieri, Ferdinando Luberto, Stefania Caroli, Marina Greci, Paolo Giorgi Rossi, Valeria Manicardi

    The objective of this study is to assess the impact of diabetes on cardiovascular mortality, focusing on sex differences. The inhabitants of Reggio Emilia province on December 31, 2009, aged 20–84 were followed up for three years for mortality. The exposure was determined using Reggio Emilia diabetes register. The age-adjusted death rates were estimated as well as the incidence rate ratios using Poisson regression model. Interaction terms for diabetes and sex were tested by the Wald test. People with diabetes had an excess of mortality, compared with nondiabetic subjects (all cause: IRR = 1.68; 95%CI 1.60–1.78; CVD: IRR = 1.61; 95%CI 1.47–1.76; AMI: IRR = 1.59; 95%CI 1.27–1.99; renal causes: IRR = 1.71; 95%CI 1.22–2.38). The impact of diabetes is greater in females than males for all causes (P=0.0321) and for CVD, IMA, and renal causes. Further studies are needed to investigate whether the difference in cardiovascular risk profile or in the quality of care delivered justifies the higher excess of mortality in females with diabetes compared to males.